PriceTargets.com logo

Morphic - MORF Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $54.25
  • Forecasted Upside: -4.81%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$56.99 As of 08/16/2024 01:00 AM ET
+0 (0.00%)
Get New Morphic Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MORF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MORF

Analyst Price Target is $54.25
▼ -4.81% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Morphic in the last 3 months. The average price target is $54.25, with a high forecast of $57.00 and a low forecast of $46.00. The average price target represents a -4.81% upside from the last price of $56.99.

This chart shows the closing price for MORF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 investment analysts is to hold stock in Morphic. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/26/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$57.00 ➝ $57.00
7/22/2024Stifel NicolausBoost TargetHold ➝ Hold$30.00 ➝ $57.00
7/9/2024TD CowenReiterated RatingBuy ➝ Hold
7/9/2024BMO Capital MarketsReiterated RatingOutperform ➝ Market Perform$52.00 ➝ $57.00
7/9/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Sector Perform$70.00 ➝ $57.00
12/8/2023CitigroupInitiated CoverageBuy$46.00
10/16/2023Leerink PartnrsReiterated RatingOutperform
9/28/2023BMO Capital MarketsLower TargetOutperform ➝ Outperform$106.00 ➝ $52.00
9/25/2023Stifel NicolausLower TargetHold ➝ Hold$61.00 ➝ $33.00
9/25/2023BTIG ResearchDowngradeBuy ➝ Neutral
8/8/2023Stifel NicolausDowngradeBuy ➝ Hold$69.00 ➝ $61.00
7/21/2023Berenberg BankInitiated CoverageBuy$75.00
4/26/2023BMO Capital MarketsBoost Target$83.00 ➝ $106.00
4/26/2023Royal Bank of CanadaBoost Target$75.00 ➝ $80.00
4/25/2023Wells Fargo & CompanyBoost Target$67.00 ➝ $80.00
3/8/2023Leerink PartnersBoost TargetOutperform$45.00 ➝ $56.00
3/8/2023SVB SecuritiesBoost Target$45.00 ➝ $56.00
11/8/2022Wells Fargo & CompanyBoost TargetOverweight$77.00 ➝ $78.00
11/3/2022Royal Bank of CanadaBoost TargetOutperform$70.00 ➝ $75.00
9/6/2022Stifel NicolausInitiated CoverageBuy$44.00
8/5/2022BMO Capital MarketsReiterated RatingBuy$83.00
8/4/2022Wells Fargo & CompanyLower TargetOverweight$79.00 ➝ $77.00
8/4/2022Royal Bank of CanadaLower TargetOutperform$76.00 ➝ $70.00
7/20/2022Leerink PartnersInitiated CoverageOutperform$45.00
3/31/2022Canaccord Genuity GroupInitiated CoverageBuy
2/28/2022BMO Capital MarketsLower Target$102.00 ➝ $83.00
2/25/2022Royal Bank of CanadaLower TargetOutperform$82.00 ➝ $76.00
2/11/2022BTIG ResearchInitiated CoverageBuy$64.00
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$81.00
5/3/2021BMO Capital MarketsLower TargetOutperform$111.00 ➝ $102.00
3/1/2021Wells Fargo & CompanyBoost Target$40.00 ➝ $103.00
2/2/2021Royal Bank of CanadaBoost TargetOutperform$35.00 ➝ $50.00
10/26/2020Royal Bank of CanadaInitiated CoverageOutperform$35.00
8/26/2020BMO Capital MarketsReiterated RatingBuy$37.00
8/11/2020BMO Capital MarketsBoost TargetOutperform$30.00 ➝ $37.00
7/5/2020BMO Capital MarketsReiterated RatingBuy
3/5/2020CowenReiterated RatingBuy
(Data available from 10/30/2019 forward)

News Sentiment Rating

1.02 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2024
  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2024
  • 11 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2024
  • 11 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2024

Current Sentiment

  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

Morphic logo
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $56.99
Low: $56.99
High: $56.99

50 Day Range

MA: $56.76
Low: $55.74
High: $56.99

52 Week Range

Now: $56.99
Low: $19.34
High: $57.00

Volume

400 shs

Average Volume

1,272,131 shs

Market Capitalization

$2.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Morphic?

The following equities research analysts have issued research reports on Morphic in the last twelve months: BMO Capital Markets, Citigroup Inc., Royal Bank of Canada, Stifel Nicolaus, and TD Cowen.
View the latest analyst ratings for MORF.

What is the current price target for Morphic?

4 Wall Street analysts have set twelve-month price targets for Morphic in the last year. Their average twelve-month price target is $54.25, suggesting a possible downside of 4.8%. BMO Capital Markets has the highest price target set, predicting MORF will reach $57.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $46.00 for Morphic in the next year.
View the latest price targets for MORF.

What is the current consensus analyst rating for Morphic?

Morphic currently has 4 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MORF, but not buy more shares or sell existing shares.
View the latest ratings for MORF.

What other companies compete with Morphic?

Other companies that are similar to Morphic include Arvinas, Syndax Pharmaceuticals, RedHill Biopharma, Catalent and Qiagen. Learn More about companies similar to Morphic.

How do I contact Morphic's investor relations team?

Morphic's physical mailing address is 35 Gatehouse Drive A2, Waltham MA, 02451. The company's listed phone number is (781) 996-0955. The official website for Morphic is www.morphictx.com. Learn More about contacing Morphic investor relations.